Alvotech Announces Changes to its Leadership Team
Retrieved on:
Thursday, December 1, 2022
University, FKA, Alvogen, Cancer, Teva Pharmaceuticals, Patient, Biosimilar, BS, Allergan, Respiratory disease, Partnership, Doctor of Philosophy, Actavis, Pharmacovigilance, DKSH, Teva, Physical pharmacy, CMO, Business administration, Woman, COVID-19, Stada Arzneimittel, Degenerative disease, Executive, Communication, Growth, Marketing, Osteoporosis, R, Management, Fine chemical, EU
Changes to the leadership team are effective January 1, 2023.
Key Points:
- Changes to the leadership team are effective January 1, 2023.
- I am thrilled to welcome Hafrun, who is recognized for her strong leadership in the pharma business, to our team.
- I am grateful to have been a part of the Alvotech story during an exciting time for the company, Mark Levick said.
- I had the privilege of working with extremely committed and talented colleagues across the entire team, establishing Alvotech as a commercial company and improving patient access to biologic medicines.